Medifast
NYSE:MED Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 53 Fair Values set on narratives written by author
WA
Consensus Narrative from 2 Analysts
GLP-1 Medications Will Intensify Competition, Impacting OPTAVIA's Future
Key Takeaways Medifast's revenue and earnings face uncertainty due to competition from GLP-1 medications and declining OPTAVIA coach numbers. Strategic transformation and new product launches may pressure profit margins, with high upfront costs and aggressive pricing strategies impacting financial performance.
View narrativeUS$16.50
FV
2.2% undervalued intrinsic discount-13.20%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
21 days ago author updated this narrative